γδ T细胞的肿瘤免疫治疗

文章预览

SCI 20 October 2024 Cancer immunotherapy by γδ T cells (Science; IF:44.7) Hayday A, Dechanet-Merville J, Rossjohn J, Silva-Santos B: Cancer immunotherapy by γδ T cells. Science 2024, 386(6717):eabq7248. Correspondence to: adrian.hayday@crick.ac.uk BACKGROUND 背景 This century has seen game-changing progress in the delivery of ab T cell–centric cancer immunotherapies, including immune checkpoint blockade, chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes, and affinity-enhanced T cell receptors (TCRs) in soluble and membrane-bound forms. Empowered by years of research elucidating key aspects of ab T cell biology, clinicians have achieved notable rates of remission in patients with hitherto deadly diseases such as metastatic melanoma and multiple myeloma. However, there is much more to do. In particular, successful immunotherapy needs to reach increased numbers of patients of diverse ethnicities with a much broader range of tumor types. It needs to do so whil ………………………………